New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
05:33 EDTAKER, KNCAYAkers Biosciences signs feasibility study deal with Konica Minolta
Akers Biosciences (AKER) has signed a feasibility study deal with Konica Minolta, Inc. (KNCAY) to develop a rapid test for the early detection of cardiac muscle tissue damage a condition commonly observed in patients suffering myocardial infarction. Heart attacks are the leading cause of death in U.S., with approximately 1.1M Americans suffering heart attacks each year. Konica Minolta, has asked Akers to study a diagnostic test based on Akers' proprietary Particle Immuno Filtration Assay, or PIFA, technology which, if successful, will facilitate the rapid detection of biomarkers present in a blood sample which can be used to identify cardiac muscle tissue damage. Such tissue damage can occur even at the early stages of a heart attack so early diagnosis could have a significant beneficial impact on patient treatment. The PIFA technology, when combined with Akers' proprietary Rapid Blood Cell Separation Technology, seraSTAT, permits the testing of whole blood from a finger prick sample allowing a test to be carried out in minutes at the point of care. Currently available tests for cardiac muscle tissue damage require a blood draw and the use of an interpretation device; and typically take 20-30 minutes to complete in a laboratory. Konica Minolta, at its own cost, has asked Akers to study a test which can be performed in under 10 minutes, using only a small blood sample obtained from a finger stick; and which can be read visually at the point of care.
News For AKER;KNCAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:10 EDTAKERAkers Biosciences granted European patent for blood separator technology
Akers Biosciences announces that the European Patent Office has issued a patent surrounding the company's novel blood separator technology and method of separating a fluid fraction from whole blood. Akers was granted U.S. patent protection for the Technology in 2011. The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. By utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. By contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment. The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT and forms a key component of the company's PIFA product range. In addition to seraSTAT's incorporation within some of the company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use